Evidence map›Paper›PMID 30456434›Full record

ArticlePituitary2019

Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey.

Lisa B Nachtigall, Niki Karavitaki, Katja Kiseljak-Vassiliades, Luma Ghalib, Hidenori Fukuoka, Luis V Syro, Daniel Kelly, Maria Fleseriu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.The Journal of clinical endocrinology and metabolism · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lisa B NachtigallNeuroendocrine Unit, Massachusetts General Hospital, Harvard Medical School Boston, Boston, MA, USA.
Niki KaravitakiInstitute of Metabolism and Systems Research, College of Medical and Dental Sciences, Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, University of Birmingham, Birmingham, UK.
Katja Kiseljak-VassiliadesDivision of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine at Colorado Anschutz Medical Campus, Aurora, CO, USA.
Luma GhalibDivision of Endocrinology, Ohio State University, Columbus, OH, USA.
Hidenori FukuokaDivision of Diabetes and Endocrinology, Kobe University Hospital, Kobe, Japan.
Luis V SyroDepartment of Neurosurgery, Hospital Pablo Tobon Uribe and Clinica Medellin, Medellín, Colombia.
Daniel KellyPacific Neuroscience Institute & John Wayne Cancer Institute, Santa Monica, CA, USA.
Maria FleseriuDepartments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health & Science University, Mail Code: CH8N, 3303 SW Bond Ave., Portland, OR, 97239, USA. fleseriu@ohsu.edu.ORCID http://orcid.org/0000-0001-9284-6289

Funding

Identifying and Characterizing Therapeutic Targets in Adrenal CancerK08CA222620 · NCI · UNIVERSITY OF COLORADO DENVER · PI KISELJAKVASSILIADES, KATJA · 2018 to 2022
$1.0M
NCI NIH HHS K08 CA222620
6 · The paper itself

Abstract

purposeIn view of mounting attention related to possible brain retention of gadolinium-based contrast agents (GBCAs) in patients with normal renal function, our purpose was to detail results from a survey of pituitary experts to assess: 1) the timing interval and frequency of pituitary magnetic resonance imaging (MRI) following surgical and/or medical and/or radiation therapy of pituitary tumors, 2) awareness of the types of GBCAs used and their possible safety issues.

methodsThe Pituitary Society Education Committee composed a survey with 12 multiple choice questions, 8 of which specifically addressed the time interval and frequency of MRI in the longitudinal management of pituitary tumors. The survey was distributed at two meetings; the International Pituitary Neurosurgeons Society conference in San Diego, CA, on February 18th, 2018, and the Pituitary Society Membership and Career Development Forum, Chicago, IL on March 18th, 2018.

resultsThere is consensus among pituitary endocrinologists and neurosurgeons that long-term repeated imaging is recommended in most pituitary tumors, although the precise strategy of timing varied depending on the specialist group and the specific clinical context of the adenoma. The data also suggest that International Pituitary Neurosurgeons Society neurosurgeons, as well as Pituitary Society neuroendocrinologists, are sometimes unaware of which contrast agents are used by their institution, and many are also unaware that evidence of long-term brain retention has been reported with the use of GBCAs in patients with normal function.

conclusionsInternational pituitary endocrinologists and pituitary neurosurgeons experts suggest ongoing MRIs for the management of pituitary tumors; strategies vary based on clinical context, but also on individual experience and practice.

Indexed as

AdenomaContrast MediaGadoliniumHumansMagnetic Resonance ImagingPituitary NeoplasmsSurveys and QuestionnairesContrast MediaGadoliniumAdenomaContrastGadoliniumImagingNeuroendocrinologistsNeurosurgeonsPituitarySafetySurveyTumor

Identifiers

PMID30456434
PMCPMC6697166

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.